By FSD Pharma on Tuesday, 02 July 2019
Category: Vertically Integrated

FSD Pharma closes Prismic Pharmaceuticals acquisition

viewFSD Pharma

Inc (CSE: HUGE) (OTCMKTS:FSDDF) President Edward Brennan tells Proactive Investors the cannabis focused company has closed on a $17.5 million deal to acquire US-based specialty research and development pharma company Prismic Pharmaceuticals Inc.

Dr Brennan also offered investors a glimpse into his professional background which includes stints as the general surgeon at () and (NYSE:GSK).

CSE:HUGE

Market: CSE
Market Cap: $63.39 m
Follow

View company profile

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Most read

FSD Pharma rings the Nasdaq opening bell in 'exciting and momentous moment'

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) CEO Raza Bokhari, who runs the pharmaceutical cannabis research company, rang the Nasdaq opening bell together with with members of the board, leadership team, early investors, and others. Bokhari says it was an 'exciting and momentous moment' for the...

1 week, 2 days ago

2 min read

Related Posts